← FDA DRUG APPROVALS

FDA ANDA · ANDA087264

THIORIDAZINE HYDROCHLORIDE

Sponsor: MUTUAL PHARM

APPLICATION
ANDA087264
TYPE
ANDA
ORIGINAL APPROVAL
1983-11-18
LATEST ACTION
2010-12-03
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

THIORIDAZINE HYDROCHLORIDEDiscontinued
THIORIDAZINE HYDROCHLORIDE 25MG · TABLET · ORAL

Approval history

2010-12-03Labeling · Supplement 30AP
1998-12-01Manufacturing (CMC) · Supplement 29AP
1994-12-23Manufacturing (CMC) · Supplement 28AP
1994-10-11Manufacturing (CMC) · Supplement 27AP
1992-04-03Manufacturing (CMC) · Supplement 26AP
1992-04-03Manufacturing (CMC) · Supplement 24AP
1991-08-30Manufacturing (CMC) · Supplement 20AP
1991-08-30Manufacturing (CMC) · Supplement 23AP
1990-06-12Bioequivalence · Supplement 14AP
1990-02-23Labeling · Supplement 22AP
1989-03-28Labeling · Supplement 18AP
1989-03-28Manufacturing (CMC) · Supplement 19AP
1989-03-28Manufacturing (CMC) · Supplement 17AP
1988-08-19Labeling · Supplement 16AP
1988-06-02Labeling · Supplement 15AP
1988-03-03Manufacturing (CMC) · Supplement 11AP
1988-03-03Manufacturing (CMC) · Supplement 12AP
1987-04-01Manufacturing (CMC) · Supplement 10AP
1986-04-17Manufacturing (CMC) · Supplement 8AP
1986-04-17Manufacturing (CMC) · Supplement 6AP
1986-04-17Manufacturing (CMC) · Supplement 4AP
1986-04-17Manufacturing (CMC) · Supplement 9AP
1986-04-17Manufacturing (CMC) · Supplement 5AP
1985-11-22Manufacturing (CMC) · Supplement 3AP
1983-11-18OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →